Safety of 3‐Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus‐Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART‐CHOICE Trial

BACKGROUND: This study sought to investigate the safety of 3‐month dual antiplatelet therapy (DAPT) in patients receiving ultrathin sirolimus‐eluting stents with biodegradable polymer (Orsiro). METHODS AND RESULTS: The SMART‐CHOICE (Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonis...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Kyeong Ho, Lee, Seung‐Yul, Cho, Byung Ryul, Jang, Woo Jin, Song, Young Bin, Oh, Ju‐Hyeon, Chun, Woo Jung, Park, Yong Hwan, Im, Eul‐Soon, Jeong, Jin‐Ok, Oh, Seok Kyu, Cho, Deok‐Kyu, Lee, Jong‐Young, Koh, Young‐Youp, Bae, Jang‐Whan, Choi, Jae Woong, Lee, Wang Soo, Yoon, Hyuck Jun, Lee, Seung Uk, Cho, Jang Hyun, Choi, Woong Gil, Rha, Seung‐Woon, Lee, Joo Myung, Park, Taek Kyu, Yang, Jeong Hoon, Choi, Jin‐Ho, Choi, Seung‐Hyuck, Lee, Sang Hoon, Gwon, Hyeon‐Cheol, Hahn, Joo‐Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955499/
https://www.ncbi.nlm.nih.gov/pubmed/33345567
http://dx.doi.org/10.1161/JAHA.120.018366
Descripción
Sumario:BACKGROUND: This study sought to investigate the safety of 3‐month dual antiplatelet therapy (DAPT) in patients receiving ultrathin sirolimus‐eluting stents with biodegradable polymer (Orsiro). METHODS AND RESULTS: The SMART‐CHOICE (Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Anti‐ platelet Therapy in Patients Undergoing Implantation of Coronary Drug‐Eluting Stents) randomized trial compared 3‐month DAPT followed by P2Y12 inhibitor monotherapy with 12‐month DAPT in 2993 patients undergoing percutaneous coronary intervention. The present analysis was a prespecified subgroup analysis for patients receiving Orsiro stents. As a post hoc analysis, comparisons between Orsiro and everolimus‐eluting stents were also done among patients receiving 3‐month DAPT. Of 972 patients receiving Orsiro stents, 481 patients were randomly assigned to 3‐month DAPT and 491 to 12‐month DAPT. At 12 months, the target vessel failure, defined as a composite of cardiac death, target vessel–related myocardial infarction, or target vessel revascularization, occurred in 8 patients (1.7%) in the 3‐month DAPT group and in 14 patients (2.9%) in the 12‐month DAPT group (hazard ratio [HR], 0.58; 95% CI, 0.24–1.39; P=0.22). In whole population who were randomly assigned to receive 3‐month DAPT (n=1495), there was no significant difference in the target vessel failure between the Orsiro group and the everolimus‐eluting stent group (n=1014) (1.7% versus 1.8%; HR, 0.96; 95% CI, 0.41–2.22; P=0.92). CONCLUSIONS: In patients receiving Orsiro stents, clinical outcomes at 1 year were similar between the 3‐month DAPT followed by P2Y12 inhibitor monotherapy and 12‐month DAPT strategies. With 3‐month DAPT, there was no significant difference in target vessel failure between Orsiro and everolimus‐eluting stents. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02079194.

Ejemplares similares